𝔖 Bobbio Scriptorium

✦ LIBER ✦

211Pharmacokinetics of IV Busulfan (IV BU) in pediatric infants (< 10-kilogram body weight) undergoing stem cell transplant

✍ Scribed by J. Dalle; D. Wall; M. Duval; Y. Theoret; C. Taylor; M. Vachon; A. Moghrabi; D. Larocque; M.A. Champagne

Book ID: 117728209
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 264 KB
Volume: 9
Category: Article
ISSN: 1083-8791
DOI: 10.1016/s1083-8791(03)80204-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Twice-Daily Intravenous (IV) Busulfan (B

Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days In Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Pharmacokinetically Similar to Q6 Hour Dosing in the Pediatric Population

✍ I. Waxman; M.C. Milone; M. Bhatia; L. Shaw; V. Moore; B. Tallamy; O. Militano; J 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Iv Busulfan Administered Q12 Vs Q6 Hrs D

Iv Busulfan Administered Q12 Vs Q6 Hrs During Conditioning of Pediatric Allogeneic Stem Cell Transplant (AlloSCT) Recipients Has Comparable Pharmacokinetics and Significant Reduction in Nursing/Pharmacist Costs

✍ J. LeGall; M.C. Milone; I.M. Waxman; L.M. Shaw; L. Harrison; D. Duffy; O. Milita 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Intravenous (IV) Busulfan (Bu) Administe

Intravenous (IV) Busulfan (Bu) Administered Twice Daily During Conditioning Prior to Allogeneic Stem Cell Transplant (AlloSCT) in Pediatric Recipients Has Significantly Different Half-Life of Elimination and Clearance in Recipients >4 Years and Those ≤ 4 Years

✍ J.B. LeGall; M. Milone; I. Waxman; L. Shaw; L. Harrison; D. Duffy; C. van de Ven 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 70 KB

229: Twice-Daily Intravenous (IV) Busulf

229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults

✍ I. Waxman; M. Bhatia; M. Milone; L.M. Shaw; L. Baldinger; O. Militano; J. Garvin 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Identification of an AUC of 7603 Umol∗Mi

Identification of an AUC of 7603 Umol∗Min/Hr Per Day X 4 Days as the Maximum Tolerated Dose (MTD) of IV Continuous Infusion (CI) Busulfan (BU) with Fixed Dose Fludarabine (FLU) in A Pharmacokinetically-Based Dose Phase I Study in Patients (PTS) with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

✍ W.A. Wood; C.M. Walko; K.V. Rao; J. Whitley; D.T. Moore; D.A. Gabriel; J.S. Sero 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 45 KB